Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720213 · ClinicalTrials.gov registry record · NA
Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device
A NA study, sponsored by Philips Respironics.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT00720213 is a NA study that has completed, run by Philips Respironics. The registered enrollment target is 44 participants.
The verdict
NCT00720213, a NA study, has completed, sponsored by Philips Respironics.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study is being undertaken to collect data from Respironics Inc's BiPAP Auto Servo Ventilation 3 (autoSV3) and compare with data from Respironics, Inc's BiPAP autoSV2, to confirm that the algorithms in the BiPAP autoSV3 device can safely and effectively treat participants experiencing Complex Sleep Apneas (Comp SAS) no worse than its predecessor, the BiPAP auto Servo ventilation 2 (autoSV2) device. This will be determined using a comparative, randomized design with the participants blinded to the therapy. Additionally, attempts will be made to blind the central scorer(s) with respect to which device is in use.
Interventions
- DEVICE Respironics BiPAP autoSV2
- DEVICE Respironics BiPAP autoSV3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720213
The ClinicalTrials.gov registry entry for NCT00720213 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philips Respironics, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Respironics BiPAP autoSV2 is the first listed.
NCT00720213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720213 about?
NCT00720213 is a clinical study titled "Evaluation of Software Enhancements to the Respironics BiPAP Auto Servo Ventilation (AutoSV) Device". This study is being undertaken to collect data from Respironics Inc's BiPAP Auto Servo Ventilation 3 (autoSV3) and compare with data from Respironics, Inc's BiPAP autoSV2, to confirm that the algorithms in the BiPAP autoSV3 device can safely and effectively treat participants experiencing Complex Sl...
What is the current status of trial NCT00720213?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2008-08. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00720213?
The interventions under investigation include: Respironics BiPAP autoSV2 (DEVICE), Respironics BiPAP autoSV3 (DEVICE).
Who is sponsoring clinical trial NCT00720213?
This trial is sponsored by Philips Respironics, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.